| Patent application number | Description | Published |
|---|
| 20080200890 | ANTIMICROBIAL DISPOSABLE ABSORBENT ARTICLES - Disposable absorbent articles comprising an absorbent material and a degradable thermoplastic polymer composition comprising an aliphatic polyester and an antimicrobial composition. The antimicrobial composition includes an antimicrobial component and an enhancer component. The aliphatic polyester and antimicrobial composition are formed into webs by melt extrusion, such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, panty liners and tampons, personal care wipes and household wipes to provide odor control, control of microbial growth, and control of microbial toxin production. | 08-21-2008 |
| 20090093514 | IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 04-09-2009 |
| 20100096287 | Immune Response Modifier Compositions and Methods - A pharmaceutical composition comprising 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine that is stable to sterilization and suitable for topical application directly to tissue sites where the dermis has been breached, and has been sterilized, packaged compositions that have been sterilized, and methods of sterilizing these compositions are disclosed. | 04-22-2010 |
| 20100120819 | METHOD OF REDUCING IMIQUIMOD IMPURITY FORMATION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120820 | METHOD OF TREATING ACTINIC KERATOSIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120821 | METHOD OF TREATING GENITAL OR PERI-ANAL WARTS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120822 | METHOD OF CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES (BHA COMPARATOR) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120823 | METHOD OF TREATING BASAL CELL CARCINOMA - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120824 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120825 | METHOD OF TREATING MOLLESCUM CONTAGIOSUM - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120826 | METHOD OF INDUCING CYTOKINE BIOSYNTHESIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120827 | X-FOLD LESS IMIQUIMOD IMPURITIES AT TWO MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120828 | METHOD OF INDUCING INTERFERON BIOSYNTHESIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120829 | X-FOLD LESS IMIQUIMOD IMPURITIES AT SIX MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120830 | PHARMACEUTICAL CREAM HAVING SIMILAR OR LESS LEVELS OF IMIQUIMOD IMPURITY FORMATION AS CREAM WITH BHA (COMPARATOR) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120831 | METHODS FOR IMPROVING IMIQUIMOD AVAILABILITY AT TWO MONTHS, FOUR MONTHS AND SIX MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120832 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST FOUR MONTHS STORAGE) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120833 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST SIX MONTHS STORAGE) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120834 | REDUCTION OF IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120835 | PHARMACEUTICAL CREAM WITH REDUCED IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120836 | METHOD OF TREATING A DERMAL AND/OR MUCOSAL ASSOCIATED CONDITION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100120837 | METHOD OF TREATING A MUCOSAL AND/OR DERMAL ASSOCIATED CONDITION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
| 20100130529 | METHOD OF STABILIZING IMIQUIMOD - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130530 | REDUCTION OF IMIQUIMOD IMPURITIES USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130531 | PHARMACEUTICAL CREAMS WITH REDUCED IMIQUIMOD IMPURITIES - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130532 | REDUCTION OF IMIQUIMOD IMPURITIES IN PHARMACEUTICAL CREAMS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130533 | PHARMACEUTICAL CREAMS WITH REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130534 | METHODS FOR REDUCING IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130535 | METHODS FOR STABILIZING IMIQUIMOD FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
| 20100130536 | METHODS FOR CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
